Immune aspects of the pathogenesis of inflammatory bowel disease

Tadakazu Hisamatsu, Takanori Kanai, Yohei Mikami, Kazuaki Yoneno, Katsuyoshi Matsuoka, Toshifumi Hibi

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Although the precise etiologies of inflammatory bowel disease (IBD) (ulcerative colitis and Crohn's disease) remain obscure, several reports have indicated that dysfunction of the mucosal immune system plays an important role in its pathogenesis. Recent progress with genome-wide association studies has identified many IBD susceptibility genes. In individuals with genetic risk, abnormal interactions between the host immune system and gut flora, and dysregulation of cellular responses such as autophagy and ER stress, induce an abnormal host immune response in the gut resulting in intestinal inflammation. Research progress animal models in IBD, and in human IBD, has identified several key molecules in IBD pathogenesis such as TNFα and adhesion molecules, and molecular targeting therapies based on these molecules have been developed. Here, we review immunological aspects in IBD pathogenesis and the development of immunoregulatory therapy.

Original languageEnglish
Pages (from-to)283-297
Number of pages15
JournalPharmacology and Therapeutics
Volume137
Issue number3
DOIs
Publication statusPublished - 2013 Mar

Fingerprint

Inflammatory Bowel Diseases
Immune System
Genome-Wide Association Study
Disease Susceptibility
Autophagy
Ulcerative Colitis
Crohn Disease
Animal Models
Inflammation
Therapeutics
Research
Genes

Keywords

  • Autophagy
  • Cytokines
  • ER stress
  • Innate and acquired immunity
  • Micobiota
  • Molecular targeting therapy
  • Susceptibility gene

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Immune aspects of the pathogenesis of inflammatory bowel disease. / Hisamatsu, Tadakazu; Kanai, Takanori; Mikami, Yohei; Yoneno, Kazuaki; Matsuoka, Katsuyoshi; Hibi, Toshifumi.

In: Pharmacology and Therapeutics, Vol. 137, No. 3, 03.2013, p. 283-297.

Research output: Contribution to journalArticle

Hisamatsu, Tadakazu ; Kanai, Takanori ; Mikami, Yohei ; Yoneno, Kazuaki ; Matsuoka, Katsuyoshi ; Hibi, Toshifumi. / Immune aspects of the pathogenesis of inflammatory bowel disease. In: Pharmacology and Therapeutics. 2013 ; Vol. 137, No. 3. pp. 283-297.
@article{e85575e27565481ba766c21f9f4f4bd6,
title = "Immune aspects of the pathogenesis of inflammatory bowel disease",
abstract = "Although the precise etiologies of inflammatory bowel disease (IBD) (ulcerative colitis and Crohn's disease) remain obscure, several reports have indicated that dysfunction of the mucosal immune system plays an important role in its pathogenesis. Recent progress with genome-wide association studies has identified many IBD susceptibility genes. In individuals with genetic risk, abnormal interactions between the host immune system and gut flora, and dysregulation of cellular responses such as autophagy and ER stress, induce an abnormal host immune response in the gut resulting in intestinal inflammation. Research progress animal models in IBD, and in human IBD, has identified several key molecules in IBD pathogenesis such as TNFα and adhesion molecules, and molecular targeting therapies based on these molecules have been developed. Here, we review immunological aspects in IBD pathogenesis and the development of immunoregulatory therapy.",
keywords = "Autophagy, Cytokines, ER stress, Innate and acquired immunity, Micobiota, Molecular targeting therapy, Susceptibility gene",
author = "Tadakazu Hisamatsu and Takanori Kanai and Yohei Mikami and Kazuaki Yoneno and Katsuyoshi Matsuoka and Toshifumi Hibi",
year = "2013",
month = "3",
doi = "10.1016/j.pharmthera.2012.10.008",
language = "English",
volume = "137",
pages = "283--297",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Immune aspects of the pathogenesis of inflammatory bowel disease

AU - Hisamatsu, Tadakazu

AU - Kanai, Takanori

AU - Mikami, Yohei

AU - Yoneno, Kazuaki

AU - Matsuoka, Katsuyoshi

AU - Hibi, Toshifumi

PY - 2013/3

Y1 - 2013/3

N2 - Although the precise etiologies of inflammatory bowel disease (IBD) (ulcerative colitis and Crohn's disease) remain obscure, several reports have indicated that dysfunction of the mucosal immune system plays an important role in its pathogenesis. Recent progress with genome-wide association studies has identified many IBD susceptibility genes. In individuals with genetic risk, abnormal interactions between the host immune system and gut flora, and dysregulation of cellular responses such as autophagy and ER stress, induce an abnormal host immune response in the gut resulting in intestinal inflammation. Research progress animal models in IBD, and in human IBD, has identified several key molecules in IBD pathogenesis such as TNFα and adhesion molecules, and molecular targeting therapies based on these molecules have been developed. Here, we review immunological aspects in IBD pathogenesis and the development of immunoregulatory therapy.

AB - Although the precise etiologies of inflammatory bowel disease (IBD) (ulcerative colitis and Crohn's disease) remain obscure, several reports have indicated that dysfunction of the mucosal immune system plays an important role in its pathogenesis. Recent progress with genome-wide association studies has identified many IBD susceptibility genes. In individuals with genetic risk, abnormal interactions between the host immune system and gut flora, and dysregulation of cellular responses such as autophagy and ER stress, induce an abnormal host immune response in the gut resulting in intestinal inflammation. Research progress animal models in IBD, and in human IBD, has identified several key molecules in IBD pathogenesis such as TNFα and adhesion molecules, and molecular targeting therapies based on these molecules have been developed. Here, we review immunological aspects in IBD pathogenesis and the development of immunoregulatory therapy.

KW - Autophagy

KW - Cytokines

KW - ER stress

KW - Innate and acquired immunity

KW - Micobiota

KW - Molecular targeting therapy

KW - Susceptibility gene

UR - http://www.scopus.com/inward/record.url?scp=84874108251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874108251&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2012.10.008

DO - 10.1016/j.pharmthera.2012.10.008

M3 - Article

C2 - 23103332

AN - SCOPUS:84874108251

VL - 137

SP - 283

EP - 297

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

IS - 3

ER -